We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights Alphabet, Roche Holding, Honeywell International, IBM and The Goldman Sachs
Read MoreHide Full Article
For Immediate Release
Chicago, IL – August 29, 2023 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Alphabet Inc. (GOOGL - Free Report) , Roche Holding AG (RHHBY - Free Report) , Honeywell International Inc. (HON - Free Report) , IBM Corp. (IBM - Free Report) and The Goldman Sachs Group, Inc. (GS - Free Report) .
Here are highlights from Monday’s Analyst Blog:
Top Stock Reports for Alphabet, Roche and Honeywell
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Alphabet Inc., Roche Holding AG and Honeywell International Inc. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Alphabet shares have outperformed the Zacks Tech sector (+48% vs. +35%) as well as the S&P 500 index (+48% vs. +15.5%) in the year-to-date period on the back of the company's central role in the evolving artificial intelligence (AI) developments. Adding to the AI hopes is the company's strong cloud division and improving outlook for the digital ad market.
Also, strong focus on innovation of AI techniques and the home automation space should aid business growth in the long term. Further, its deepening focus on the wearables category remains a tailwind. Alphabet's expanding presence in the autonomous driving space is contributing well. Its growing efforts to gain a foothold in the healthcare industry are other positives.
However, sluggishness in the company's Network advertisement business remains a headwind. Additionally, its growing litigation issues and increasing expenses are concerns.
Shares of Roche have gained +4.3% over the past six months against the Zacks Large Cap Pharmaceuticals industry's gain of +18.8%. The company's new drugs, namely Ocrevus, Hemlibra, Evrysdi, Phesgo, Polivy and Tecentriq, recorded growth and should maintain momentum. The uptake of the new eye drug, Vabysmo has been outstanding. The company's efforts to develop new drugs to combat the decline in legacy drugs are encouraging.
However, Roche's performance in the first half was average as COVID-19-product-related sales declined significantly impacting the top line, even though the diagnostics base business and newer drugs maintained their growth.
Also, sales are likely to be affected further by the expected nosedive in sales of COVID-19 products of nearly CHF 5 billion. Competition from biosimilars for established cancer medicines like Avastin, MabThera/Rituxan and Herceptin also hurt sales.
Shares of Honeywell International have underperformed the Zacks Diversified Operations industry over the past year (-1.1% vs. +3.3%). The company is witnessing supply-chain disruptions which remain a concern. Weakness in the Safety and Productivity Solutions unit due to lower warehouse, and workflow and productivity solutions volumes is worrisome. Raw material cost inflation and adverse foreign currency movements are other concerns.
Nevertheless, Recovery in commercial flight hours, strength in process solutions and UOP businesses augur well for Honeywell's growth. Solid operational execution, pricing actions and cost-control measures continue to drive the company's top line. HON's bullish forecast for 2023 holds promise.
Handsome rewards to shareholders add to the stock's appeal. HON's recent acquisition of Compressor Controls enhances its expertise in industrial control, automation and process solutions.
Other noteworthy reports we are featuring today include IBM Corp. and The Goldman Sachs Group, Inc.
Why Haven't You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +6.2 average gain per year. Amazingly, they soared with average gains of +46.4%, +49.5% and +55.2% per year. Today you can access their live picks without cost or obligation.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights Alphabet, Roche Holding, Honeywell International, IBM and The Goldman Sachs
For Immediate Release
Chicago, IL – August 29, 2023 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Alphabet Inc. (GOOGL - Free Report) , Roche Holding AG (RHHBY - Free Report) , Honeywell International Inc. (HON - Free Report) , IBM Corp. (IBM - Free Report) and The Goldman Sachs Group, Inc. (GS - Free Report) .
Here are highlights from Monday’s Analyst Blog:
Top Stock Reports for Alphabet, Roche and Honeywell
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Alphabet Inc., Roche Holding AG and Honeywell International Inc. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today's research reports here >>>
Alphabet shares have outperformed the Zacks Tech sector (+48% vs. +35%) as well as the S&P 500 index (+48% vs. +15.5%) in the year-to-date period on the back of the company's central role in the evolving artificial intelligence (AI) developments. Adding to the AI hopes is the company's strong cloud division and improving outlook for the digital ad market.
Also, strong focus on innovation of AI techniques and the home automation space should aid business growth in the long term. Further, its deepening focus on the wearables category remains a tailwind. Alphabet's expanding presence in the autonomous driving space is contributing well. Its growing efforts to gain a foothold in the healthcare industry are other positives.
However, sluggishness in the company's Network advertisement business remains a headwind. Additionally, its growing litigation issues and increasing expenses are concerns.
(You can read the full research report on Alphabet here >>>)
Shares of Roche have gained +4.3% over the past six months against the Zacks Large Cap Pharmaceuticals industry's gain of +18.8%. The company's new drugs, namely Ocrevus, Hemlibra, Evrysdi, Phesgo, Polivy and Tecentriq, recorded growth and should maintain momentum. The uptake of the new eye drug, Vabysmo has been outstanding. The company's efforts to develop new drugs to combat the decline in legacy drugs are encouraging.
However, Roche's performance in the first half was average as COVID-19-product-related sales declined significantly impacting the top line, even though the diagnostics base business and newer drugs maintained their growth.
Also, sales are likely to be affected further by the expected nosedive in sales of COVID-19 products of nearly CHF 5 billion. Competition from biosimilars for established cancer medicines like Avastin, MabThera/Rituxan and Herceptin also hurt sales.
(You can read the full research report on Roche here >>>)
Shares of Honeywell International have underperformed the Zacks Diversified Operations industry over the past year (-1.1% vs. +3.3%). The company is witnessing supply-chain disruptions which remain a concern. Weakness in the Safety and Productivity Solutions unit due to lower warehouse, and workflow and productivity solutions volumes is worrisome. Raw material cost inflation and adverse foreign currency movements are other concerns.
Nevertheless, Recovery in commercial flight hours, strength in process solutions and UOP businesses augur well for Honeywell's growth. Solid operational execution, pricing actions and cost-control measures continue to drive the company's top line. HON's bullish forecast for 2023 holds promise.
Handsome rewards to shareholders add to the stock's appeal. HON's recent acquisition of Compressor Controls enhances its expertise in industrial control, automation and process solutions.
(You can read the full research report on Honeywell International here >>>)
Other noteworthy reports we are featuring today include IBM Corp. and The Goldman Sachs Group, Inc.
Why Haven't You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +6.2 average gain per year. Amazingly, they soared with average gains of +46.4%, +49.5% and +55.2% per year. Today you can access their live picks without cost or obligation.
See Stocks Free >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.